Masimo Co. (NASDAQ:MASI – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $144.67.
MASI has been the topic of several research reports. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Friday, September 20th. Piper Sandler raised their target price on shares of Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th.
Get Our Latest Stock Report on MASI
Institutional Investors Weigh In On Masimo
Masimo Stock Up 0.1 %
Shares of MASI opened at $133.20 on Monday. The firm has a market cap of $7.08 billion, a PE ratio of 90.61 and a beta of 0.98. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The company’s fifty day moving average is $116.67 and its two-hundred day moving average is $124.97. Masimo has a fifty-two week low of $75.22 and a fifty-two week high of $153.93.
Masimo (NASDAQ:MASI – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. The firm had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.62 earnings per share. Analysts forecast that Masimo will post 3.87 earnings per share for the current year.
About Masimo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Read More
- Five stocks we like better than Masimo
- What Do S&P 500 Stocks Tell Investors About the Market?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.